Multi-Center Randomized Phase II Study Comparing Cediranib plus Gefitinib with Cediranib plus Placebo in Subjects with Recurrent/Progressive Glioblastoma.
Authors
Brown, NMcBain, Catherine A
Nash, S
Hopkins, K
Sanghera, P
Saran, F
Phillips, M
Dungey, F
Clifton-Hadley, L
Wanek, K
Krell, D
Jeffries, S
Khan, I
Smith, P
Mulholland, P
Affiliation
University College London Hospitals, LondonIssue Date
2016
Metadata
Show full item recordAbstract
Cediranib, an oral pan-vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor, failed to show benefit over lomustine in relapsed glioblastoma. One resistance mechanism for cediranib is up-regulation of epidermal growth factor receptor (EGFR). This study aimed to determine if dual therapy with cediranib and the oral EGFR inhibitor gefitinib improved outcome in recurrent glioblastoma.Citation
Multi-Center Randomized Phase II Study Comparing Cediranib plus Gefitinib with Cediranib plus Placebo in Subjects with Recurrent/Progressive Glioblastoma. 2016, 11 (5):e0156369 PLoS ONEJournal
PloS OneDOI
10.1371/journal.pone.0156369PubMed ID
27232884Type
ArticleLanguage
enISSN
1932-6203ae974a485f413a2113503eed53cd6c53
10.1371/journal.pone.0156369